1423M0634: A Phase 3 Randomised, Double‐blind, Placebo‐controlled Study to Assess the Safety and Efficacy of S‐888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Elective Invasive Procedures (L‐PLUS 2)

November 15, 2015
9745
Gastroenterology - Stomach
Principal Investigator: Stuart C Gordon, MD
The purpose of this research study is to determine the safety and effectiveness (that is, whether a drug works and whether it is as safe as expected) and the pharmacokinetics (that is, the way the body handles a drug, including how the body absorbs, circulates, breaks down and gets rid of a drug) of S‐888711 in subjects with chronic liver disease and thrombocytopenia (a low level of platelets in blood), who are scheduled to undergo elective (not urgently necessary) surgical procedures.

Please contact us for a full list of criteria.

Open
liverstudies@hfhs.org